Are you financing life science innovation?

The question of who will fund the venture capital industry moving forward is at the top of many traditional VC’s minds. Combined with decreases in up-front payments (and the rise of tranched deals), a locked down IPO market and LPs demanding quicker exits this makes for a challenging environment where only those funds with a strong track record, strategy and team will flourish.

Corporate venture capital funds, whilst shielded from many problems plaguing the traditional VC industry, still face challenges in sourcing attractive deals, staunch competition from other CVCs and the challenge of justifying their existence to their corporate backers.

BioBusiness tackles these key issues whilst providing an unmatched opportunity to network with key industry players, innovative biotechs seeking funding and provides you with the knowledge required to forge an effective strategy to operate successfully in this challenging market whilst breaking down the barrier between speakers and delegates and facilitating open and organic networking.

Just a some of the BioBusiness speakers you'll meet in 2012:

• Andrew Sandham, Chairman & CEO, Kymab
• Carl Firth, Chief Executive Officer & Founder, ASLAN Pharmaceuticals
• Dan Zabrowski, Global Head of Pharma Partnering, Roche
• David Nicholson, SVP & Head Worldwide Licensing and Knowledge Management, Merck
• Dimitri Dimitriou, Chief Executive Officer, ImmuPharma
• Dirk Reyn, Managing Director, Shire-Movetis
• Edwin Moses, CEO, Ablynx
• George Yeh, President, Taiwan Liposome Company (TLC)
• Herve Lilliu, Vice President Global Health Outcomes, Market Access and Pricing, UCB
• Ian Nicholson, CEO, Chroma Therapeutics
• James Sabry, Vice President, Genentech Partnering
• John Adamou, Head, Strategic Transactions & Alliance Management, Boehringer Ingelheim
• Jon Williams, SVP of Strategy, Business Development & Comparative Effectiveness, Medco
• Kevin FitzGerald, CEO, F-star
• Lee Eng Hin, Executive Director, BMRC, A*STAR
• Malcolm Weir, CEO, Heptares Therapeutics
• Melanie Lee, CEO, Syntaxin
• Nicholas Adams, Chief Business Officer, Clavis Pharma
• Onno van de Stolpe, CEO, Galapagos
• Patrik De Haes, CEO, ThromboGenics
• Peter Nolan, Executive Director, SVP Commercial Development, Oxford BioMedica
• Simon Sturge, Corporate Senior Vice President Biopharmaceuticals, Boehringer Ingelheim
• Steven Holtzman, Executive Vice President, Corporate Development, Biogen Idec
• Tehseen Salimi, VP, Global Evidence & Value Development Medical Affairs, Sanofi
• Tim Brears, CEO, Xention
• Werner Lanthaler, CEO, Evotec

4 reasons why you MUST attend:

• How the payer’s perspective will impact on your future returns
  How payer, reimbursement and market access issues need to be at the forefront of mind when assessing technologies and how they will impact on the exit potential of a portfolio company
• Reverse engineer drug development to meet changing payer requirements in a new era of reimbursement with panels and case studies from Medco, Sanofi, UCB and more
• Network with key innovative biotechs with promising innovation and maintain connections with industry leading pharma execs to promote cooperation
  BioBusiness builds on a reputation for attracting key decision makers from innovative biotech firms, make contacts with the key pharma executives and CVC funds necessary to do business in this changing environment
• Discover case studies outlining innovation and company strategies and benefit from relationships with industry bodies such as One Nucleus, CVCs such as MSV, TRI, SR One, RVF and heads of BD&L from Merck, GSK, Roche, Pfizer, Shire-Movetis, Celgene, Genentech, BI, Debiopharm, Biogen Idec, Astellas and more.
• Benchmark your strategy against industry leading funds
  Perspectives on the future of venture capital and how top players are crafting their top-line strategy for success
• Panels and interactive round-tables outlining industry trends, investment strategies and future opportunities for chasing alpha from Index Ventures, Puretech, TVM, SR One, Imperial Innovations, Edmond de Rothschild Investment Partners and more
• Analyse the most interesting and innovative deals of 2011
  Deconstruct deal structures, up-front payment trends and discover the true drivers and outcomes behind the most interesting deals
  • Behind the scenes insight from off-the-record case studies and panels from organisations including Astellas, Roche, BI, AstraZeneca and see how CVC have contributed to these deals

PLUS: Off-the-record case studies and panels providing insight you won’t receive anywhere else, interactive and challenging breakout sessions giving you the chance to drive the debate and learn from your peers and our renown round-table sessions driven by industry experts.

Previous BioBusiness attendees include: